Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 5 8

+8 more TTM periods

ROE
13.51% 13.52% 13.02% 13.14%
ROA
6.50% 6.45% 6.46% 6.46%
ROIC
5.80% 5.56% 6.12% 5.92%
Return on Tangible Assets
36.57% 37.31% 27.84% 37.36%
Average Days of Receivables
74.45 74.33 72.91 74.37
Free Cash Flow per Share
19.84 18.25 16.81 16.26
Free Cash Flow
7,362.00 6,789.00 6,337.00 6,145.00
Capital Expenditures
(1,651.00) (1,498.00) (1,481.00) (1,506.00)
Other line items
Cash ROIC
7.67% 7.13% 6.38% 7.11%
Accounts Receivable Turnover
5.14 5.12 5.21 5.10
Accounts Payable Turnover
8.78 8.37 7.85 8.97
Inventory Turnover
4.90 4.99 5.06 4.60
Average Days of Payables
43.49 45.60 50.23 44.33
Days of Inventory on Hand
74.88 74.95 75.24 81.63
Tax Rate
(0.08) (0.07) (0.07) (0.08)
Research and Development Expense of Revenue
3.03% 3.08% 3.14% 3.23%
Selling, General and Administrative Expense of Revenue
19.48% 19.55% 19.60% 19.62%
Share Based Compensation of Revenue
0.69% 0.70% 0.70% 0.70%
Interest Coverage
5.55 5.37 5.46 5.48
Operating CF/Net income
1.29 1.21 1.17 1.16
Depreciation/Fixed assets
0.27 0.26 0.26 0.27
Capex/Depreciation
(0.56) (0.53) (0.53) (0.54)
Revenue per Share
124.89 121.50 118.19 115.70
Operating CF per Share
24.29 22.28 20.74 20.24
Capex per Share
(4.45) (4.03) (3.93) (3.98)
Capex to Sales
0.04 0.03 0.03 0.03

Fold the line items

Columns are period end dates